Immunex Corporation

Amgen Inc.

Qilu Puget Sound Biotherapeutics Corporation

William C Fanslow, Iii

Richard Jeffrey Armitage

David J Cosman

Jurgen Mullberg

Marek Z Kubin

Randal Robert Ketchem

Jiangchun Xu

Douglas Pat Cerretti

Gunasekaran Kannan

Steven R Wiley

Jason Charles O'Neill

Kristine M Kim

Michelle Blake

Mark Edward Tometsko

Melanie K Spriggs

Chadwick Terence King

Peter Robert Baum

Stewart D Lyman

Zhulun Wang

Blair R Renshaw

James F Smothers

Zhi Liu

Roy A Black

Wei Yan

Pranhitha Reddy

Luis G Borges

John M Delaney

Da Ren

Adel Youakim

Michael B Widmer

Zhonghua Hu

Yuling Zhang

Randal B Bass

Timothy E Lofton

Eric A Sorensen

Kurt M Poindexter

Zhimei Du

Feng He

Barry L Davison

Athena Sudom

Anne-Marie C Rousseau

Thomas O Daniel

Revital Kariv

Anti-CTLA4 antibodies, anti-PD1 antibodies, mixtures thereof, polynucleotides encoding such antibodies or mixtures, optionally carried on vectors, and methods of treatment utilizing such antibodies, mixtures, polynucleotides, or vectors are described herein. The anti-CTLA4 and anti-PD1 antibodies have particular sequences and properties. The methods of treatment include uses in treatment of cancer, infections, and immunodeficiency disorders.

Anti-PD1 and anti-CTLA4 antibodies

The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.

Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.

BCMA antigen binding proteins

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

BCMA Antigen binding proteins

The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.

CD27L antigen binding proteins

The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.

Tweak receptor

The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-&#x3b3; production, NK cell proliferation, and CTL activity.

ULBP2 polypeptides

The present invention provides stem cells characterized as having the ability to renew and the ability to give rise to endothelial and/or endothelial-like cells, methods of isolating such stem cells and methods of use thereof. Also provided are progeny cells derived from the stem cells of the invention.

Endothelial stem cells, populations, methods of isolation and use thereof

TWEAK receptor

ULBP antibodies

Anti-CD148 antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind CD148 epitopes and activate CD148 function, such as inhibition of angiogenesis. Epitopes that can be used to activate CD148 function and anti-angiogenesis activity are also described, as well as methods of identifying compounds that can bind them.

Antibodies of angiogenesis inhibiting domains CD148

There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.

CD40-Ligand lacking native-pattern glycosylation

Growing community of inventors

Normandy Park, WA, United States of America

William C Fanslow, Iii